Skip to content

MOST EMPOWER: Optimizing An Emotion Regulation Intervention

Using MOST to EMPOWER: Optimizing an Emotion Regulation Intervention to Enhance Well-being Among Adolescents and Young Adult Cancer Survivors

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04317417
Acronym
MOST EMPOWER
Enrollment
352
Registered
2020-03-23
Start date
2022-01-06
Completion date
2025-04-30
Last updated
2026-07-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer

Keywords

Adolescents, Young Adults, Post-treatment cancer survivors

Brief summary

This purpose of this study is to test a digital health intervention that may promote well-being among young adult cancer survivors. Investigators hope to learn more about wellness and health-related quality of life among young adult cancer survivors by promoting well-being and teaching skills for healthy coping and mood management.

Detailed description

The EMPOWER Intervention is composed of five components: 1. Noting daily positive event, capitalizing on and savoring positive events, and gratitude. 2. Mindfulness 3. Positive Reappraisal 4. Focusing on personal strengths, setting and working toward attainable goals 5. Small Acts of Kindness For subjects who do not receive EMPOWER components or only receive some of the EMPOWER components, they will be given inert content. The inert content will cover Cognitive changes during Cancer, Diet, Weight Management, Financial Literacy and Sun Protection. The trial is a composed of a full factorial design with 32 (2X2X2X2X2) experimental conditions. Adolescents and Young Adults will receive 0, 1,2,3,4 or 5 Empower components. Primary Objective • Identify which of five components in the EMPOWER web based curriculum, contribute meaningfully to positive affect among post-treatment adolescent and young adult cancer survivors. Secondary Objective * Identify which of five components in the EMPOWER web based curriculum, contribute meaningfully to depression and anxiety among post-treatment adolescent and young adult cancer survivors. * Identify which of five components in the EMPOWER web based curriculum, contribute meaningfully to meaning and purpose, life satisfaction and global mental health among post-treatment adolescent and young adult cancer survivors. Exploratory Objectives * Summarize adherence and retention by participants over the course of the EMPOWER intervention. * Identify which of five components in the EMPOWER web based curriculum, contribute meaningfully to physical functioning, fatigue, satisfaction with social roles and responsibilities. * Identify which of five components in the EMPOWER web based curriculum, contribute meaningfully to health behaviors (diet, exercise, sedentary behavior, alcohol consumption, cigarette smoking). * Examine the trajectory of change in positive affect, life satisfaction, meaning and purpose, depression, anxiety, and global mental health among post-treatment adolescent and young adult cancer survivors post intervention by intervention component. * Examine coping self-efficacy as a mediator of the relationship between EMPOWER intervention components and positive affect, life satisfaction, meaning and purpose, depression, anxiety, and global mental health. * Examine potential moderators (age, gender, social support, general self-efficacy, stressors, and positive events) of the relationship between EMPOWER intervention components and positive affect, life satisfaction, meaning and purpose, depression, anxiety and global mental health.

Interventions

BEHAVIORALEMPOWER

Participants will receive weekly material for a total of 5 weeks consisting of 1-2 days of didactic content and several days of brief, real-life skills practice and reporting taking approximately 10-15 minutes to complete. Adolescents and young adults cannot skip ahead, but they can return to old lessons or exercises if they choose. Most exercises are done in a "diary" format in which past responses are displayed next to their new ones, so that every time they visit that exercise they see their growing list of past positive experiences. Participants will be permitted up to 8 weeks to complete this self-guided intervention.

Sponsors

Wake Forest University Health Sciences
Lead SponsorOTHER
National Cancer Institute (NCI)
CollaboratorNIH

Study design

Allocation
RANDOMIZED
Intervention model
FACTORIAL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
15 Years to 39 Years
Healthy volunteers
No

Inclusion criteria

* Able to read and understand English * Past history of a cancer diagnosis (excluding basal cell skin carcinoma) * 15 to 39 years of age at diagnosis of first cancer and currently between the ages of 15 to 39 * Within 0-5 year's post-active treatment for initial diagnosis or recurrence (Note: Maintenance therapy for hematologic or hormonal therapy for breast cancers are not considered "active treatments" for purposes of this study). * Internet access through a home computer, tablet or smartphone.

Exclusion criteria

* Ever been hospitalized for a psychiatric illness * Currently receiving palliative or hospice care

Design outcomes

Primary

MeasureTime frameDescription
T0 and T6 Positive Affect T-Scores--Patient-Reported Outcomes Measurement Information System (PROMIS) Positive Affect Computer Adaptive Test (CAT) QuestionnaireAt baseline (T0) and at intervention completion 10 weeks after baseline (T6)Participants completed a self-reported questionnaire on psychological well being for feelings that reflect a level of pleasurable engagement with the environment, such as happiness, joy, excitement, enthusiasm, and contentment over the past seven days. We used a mixed model to estimate the mean within-group value of the outcome (positive affect T-score) at each time point following the intervention. Average score (50): Represents the national average for the general population. 50 indicates the population mean with a standard deviation of 10 Higher scores (\>50): Indicate higher positive affect than the general population. For example, a T-score of 60 is one standard deviation better than the national average. Lower scores (\<50): Indicate lower positive affect than the general population. A T-score of 40 is one standard deviation worse than the national average.

Secondary

MeasureTime frameDescription
T0 and T6 Anxiety T-Scores--Patient-Reported Outcomes Measurement Information System (PROMIS) Anxiety Computer Adaptive Test (CAT) QuestionnaireAt baseline (T0) and at intervention completion 10 weeks after baseline (T6)Participants completed a self-reported questionnaire on psychological well being for feelings that reflect a level of pleasurable engagement with the environment, such as happiness, joy, excitement, enthusiasm, and contentment over the past seven days. We used a mixed model to estimate the mean within-group value of the outcome (positive affect T-score) at each time point following the intervention. Average score (50): Represents the national average for the general population. 50 indicates the population mean with a standard deviation of 10 Higher scores (\>50): Indicate higher positive affect than the general population. For example, a T-score of 60 is one standard deviation better than the national average. Lower scores (\<50): Indicate lower positive affect than the general population. A T-score of 40 is one standard deviation worse than the national average.
T0 and T6 Depression T-Scores--Patient-Reported Outcomes Measurement Information System (PROMIS) Depression QuestionnaireAt baseline (T0) and at intervention completion 10 weeks after baseline (T6)Participants completed a self-reported questionnaire on psychological well being for feelings that reflect a level of pleasurable engagement with the environment, such as happiness, joy, excitement, enthusiasm, and contentment over the past seven days. We used a mixed model to estimate the mean within-group value of the outcome (positive affect T-score) at each time point following the intervention. Average score (50): Represents the national average for the general population. 50 indicates the population mean with a standard deviation of 10 Higher scores (\>50): Indicate higher positive affect than the general population. For example, a T-score of 60 is one standard deviation better than the national average. Lower scores (\<50): Indicate lower positive affect than the general population. A T-score of 40 is one standard deviation worse than the national average.
T0 and T6 Life Satisfaction T-Scores--Patient-Reported Outcomes Measurement Information System (PROMIS) Life Satisfaction QuestionnaireAt baseline (T0) and at intervention completion 10 weeks after baseline (T6)Participants completed a self-reported questionnaire on psychological well being for feelings that reflect a level of pleasurable engagement with the environment, such as happiness, joy, excitement, enthusiasm, and contentment over the past seven days. We used a mixed model to estimate the mean within-group value of the outcome (positive affect T-score) at each time point following the intervention. Average score (50): Represents the national average for the general population. 50 indicates the population mean with a standard deviation of 10 Higher scores (\>50): Indicate higher positive affect than the general population. For example, a T-score of 60 is one standard deviation better than the national average. Lower scores (\<50): Indicate lower positive affect than the general population. A T-score of 40 is one standard deviation worse than the national average.

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORJohn M Salsman, Ph.D

Wake Forest University Health Sciences

Participant flow

Pre-assignment details

The design of this study is a full factorial design with 5 arms.

Baseline characteristics

Characteristic
Age, Continuous33.0 Years
STANDARD_DEVIATION 5.9
Race/Ethnicity, Customized
Black
2 Participants
Race/Ethnicity, Customized
Other (non-Black. non-White)
2 Participants
Race/Ethnicity, Customized
White
10 Participants
Sex: Female, Male
Female
263 Participants
Sex: Female, Male
Male
1 Participants
Site
Site: Levine Cancer Institute/Hospital
1 Participants
Site
Site: MD Anderson
35 Participants
Site
Site: Northwestern
196 Participants
Site
Site: WFB/other
89 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
EG002
affected / at risk
EG003
affected / at risk
EG004
affected / at risk
EG005
affected / at risk
EG006
affected / at risk
EG007
affected / at risk
EG008
affected / at risk
EG009
affected / at risk
EG010
affected / at risk
EG011
affected / at risk
EG012
affected / at risk
EG013
affected / at risk
EG014
affected / at risk
EG015
affected / at risk
EG016
affected / at risk
EG017
affected / at risk
EG018
affected / at risk
EG019
affected / at risk
EG020
affected / at risk
EG021
affected / at risk
EG022
affected / at risk
EG023
affected / at risk
EG024
affected / at risk
EG025
affected / at risk
EG026
affected / at risk
EG027
affected / at risk
EG028
affected / at risk
EG029
affected / at risk
EG030
affected / at risk
EG031
affected / at risk
EG032
affected / at risk
EG033
affected / at risk
EG034
affected / at risk
EG035
affected / at risk
EG036
affected / at risk
EG037
affected / at risk
EG038
affected / at risk
EG039
affected / at risk
EG040
affected / at risk
EG041
affected / at risk
EG042
affected / at risk
deaths
Total, all-cause mortality
0 / 120 / 120 / 120 / 120 / 120 / 120 / 120 / 120 / 120 / 110 / 110 / 110 / 110 / 110 / 120 / 120 / 100 / 100 / 110 / 110 / 110 / 120 / 100 / 130 / 130 / 100 / 110 / 110 / 110 / 100 / 110 / 110 / 110 / 100 / 110 / 110 / 110 / 110 / 110 / 110 / 120 / 100 / 10
other
Total, other adverse events
1 / 122 / 121 / 121 / 122 / 121 / 121 / 121 / 121 / 121 / 111 / 111 / 111 / 112 / 111 / 121 / 121 / 101 / 101 / 111 / 112 / 111 / 122 / 101 / 131 / 131 / 101 / 111 / 111 / 111 / 101 / 111 / 111 / 111 / 101 / 111 / 111 / 111 / 111 / 111 / 111 / 121 / 101 / 10
serious
Total, serious adverse events
0 / 120 / 120 / 120 / 120 / 120 / 120 / 120 / 120 / 120 / 110 / 110 / 110 / 110 / 110 / 120 / 120 / 100 / 100 / 110 / 110 / 110 / 120 / 100 / 130 / 130 / 100 / 110 / 110 / 110 / 100 / 110 / 110 / 110 / 100 / 110 / 110 / 110 / 110 / 110 / 110 / 120 / 100 / 10

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 10, 2026